Kiniksa Pharmaceuticals International, plc KNSA Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's total liabilities & equity?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported total liabilities & equity of $825.28M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's total liabilities & equity changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's total liabilities & equity increased by 37.7% year-over-year, from $599.33M to $825.28M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's total liabilities & equity?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's total liabilities & equity has grown at a 16.9% compound annual growth rate (CAGR), from $349.46M to $763.63M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.